drugset / Trial / NCT04073316

AntiCoagulants and COGnition

NCT04073316

Phase 4 Unknown 48 enrolled University Hospital, Angers Bayer · collab
RandomizedParallel-groupSingle-blindSupportive care

Summary

The purpose of this study is to compare the change of global cognitive performance after 52 weeks of intervention among participants with nonvalvular atrial fibrillation (NVAF) receiving rivaroxaban versus a vitamin K antagonist (warfarin). The secondary objectives are to compare, among participants with NVFA receiving rivaroxaban versus warfarin : * the changes of global cognitive performance after 26 weeks of intervention * the changes of executive functions after 26 and 52 weeks of intervention * the changes of episodic memory after 26 and 52 weeks of intervention * the changes of independence and autonomy after 26 and 52 weeks of intervention

Timeline

Start
2020-02-13
Primary completion
2023-02
Completion
2023-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 20 mg
Comparator Warfarin Small molecule

Indications